Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer
Megan E. Tesch(Harvard University), Bernhard J. Eigl(BC Cancer Agency)
Cited by 11
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Fertility Preservation in People With Cancer: ASCO Guideline Update
|Journal of Clinical Oncology|2025|173
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
|Annals of Oncology|2015|170
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
|Clinical Cancer Research|2021|94